Q: How does Zytiga work?

Mechanism of Action Prostate cancer cells often depend on male hormones, known as androgens (such as testosterone), to grow and multiply. Zytiga belongs to a group of drugs called androgen biosynthesis inhibitors. This medication works by blocking a specific enzyme called CYP17. This enzyme is required for the body to produce androgens. Unlike some other treatments that only stop hormone production in the testes, Zytiga reduces hormone production in three different locations: The testes The adrenal glands The prostate tumor itself By lowering the levels of these hormones throughout the body, Zytiga helps slow down the progression of the cancer and may shrink existing tumors. It is typically taken in combination with a corticosteroid, such as prednisone, to help maintain a balance of other necessary hormones that the medication might otherwise affect.

Q: What are the active ingredients in Zytiga?

The active ingredient in Zytiga is abiraterone .

Q: What are the side effects of Zytiga?

Common side effects of Zytiga may include: joint pain low potassium fluid retention and others Always consult with a healthcare professional about potential side effects.

Q: What is the dosage of Zytiga and how do I take it?

How to Take Zytiga Zytiga is taken by mouth, usually once per day. It is important to take this medication on an empty stomach. You should not eat any food for at least two hours before taking your dose and for at least one hour after taking it. Taking this medicine with food can cause your body to absorb too much of the drug, which may increase the risk of side effects. The tablets should be swallowed whole with a glass of water. Do not crush, break, or chew the tablets. This medication is typically prescribed in combination with a steroid medication, such as prednisone or prednisolone, to help manage certain side effects. Missed Dose If you miss a dose of Zytiga, skip the missed dose and take your next dose at the regularly scheduled time the following day. Do not take two doses at once to make up for a missed one. If you miss more than one dose, contact your healthcare provider for instructions on how to proceed.

Q: Is Zytiga safe during pregnancy and breastfeeding?

Pregnancy and Fetal Risk Zytiga is not indicated for use in women. Clinical data suggests that exposure to this medication during pregnancy can cause significant harm to a developing fetus or lead to birth defects. The medication can be absorbed through the skin; therefore, women who are pregnant or who may become pregnant are advised to avoid handling the tablets. If handling is required, the use of protective gloves is recommended. Precautions for Men Because Zytiga may be present in semen, men with female partners of reproductive potential typically use effective contraception during and after treatment. This often includes: Using a condom along with another effective method of birth control during sexual activity. Maintaining these contraceptive practices for 3 weeks following the final dose of the medication. Breastfeeding Zytiga is not for use in women, and there is no information available regarding its safety during breastfeeding. It is unknown if the drug passes into human breast milk or what effects it may have on a nursing infant.

Q: What forms and strengths does Zytiga come in?

Zytiga is available in the following oral forms: Tablets Film-coated tablets This medication is administered by mouth. It must be taken on an empty stomach, as consuming food with the medication can significantly increase the amount of the drug absorbed by the body, potentially leading to increased side effects.

Q: What is the FDA approval status of Zytiga?

FDA Approval History The U.S. Food and Drug Administration (FDA) first approved Zytiga (abiraterone acetate) in April 2011. Initially, it was approved for patients with metastatic castration-resistant prostate cancer who had already undergone chemotherapy. Its use was later expanded in 2012 to include patients who had not yet received chemotherapy, and in 2018 for those with metastatic high-risk castration-sensitive prostate cancer. Approved Indications Zytiga is approved for use in combination with prednisone for the treatment of: Metastatic castration-resistant prostate cancer (mCRPC). Metastatic high-risk castration-sensitive prostate cancer (mCSPC). Safety and Monitoring While Zytiga does not have a Boxed Warning or a Risk Evaluation and Mitigation Strategy (REMS) program, the FDA requires specific monitoring due to risks of hepatotoxicity (liver toxicity), hypertension, and hypokalemia. Patients must have their liver function and blood pressure monitored regularly while taking this medication.

Question 1

What is Zytiga?

Accepted Answer

Zytiga is a medication classified as an androgen biosynthesis inhibitor. It functions by blocking specific enzymes in the body that are responsible for producing androgens, which are male hormones. By lowering these hormone levels, the medication helps to manage conditions that are sensitive to androgen production.

This therapy is designed to be used alongside a steroid medication. This combination approach helps the body maintain a proper balance of other essential hormones while the production of specific androgens is being suppressed.

Question 2

What is Zytiga used for?

Accepted Answer

Zytiga is used to treat prostate cancer.

Question 3

How does Zytiga work?

Accepted Answer

Mechanism of Action

Prostate cancer cells often depend on male hormones, known as androgens (such as testosterone), to grow and multiply. Zytiga belongs to a group of drugs called androgen biosynthesis inhibitors.

This medication works by blocking a specific enzyme called CYP17. This enzyme is required for the body to produce androgens. Unlike some other treatments that only stop hormone production in the testes, Zytiga reduces hormone production in three different locations:

The testes
The adrenal glands
The prostate tumor itself

By lowering the levels of these hormones throughout the body, Zytiga helps slow down the progression of the cancer and may shrink existing tumors. It is typically taken in combination with a corticosteroid, such as prednisone, to help maintain a balance of other necessary hormones that the medication might otherwise affect.

Question 4

What are the active ingredients in Zytiga?

Accepted Answer

The active ingredient in Zytiga is abiraterone.

Question 5

What are the side effects of Zytiga?

Accepted Answer

Common side effects of Zytiga may include:

joint pain
low potassium
fluid retention
and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Zytiga?

Accepted Answer

Zytiga belongs to the androgen biosynthesis inhibitor drug class.

Question 7

What is the dosage of Zytiga and how do I take it?

Accepted Answer

How to Take Zytiga

Zytiga is taken by mouth, usually once per day. It is important to take this medication on an empty stomach. You should not eat any food for at least two hours before taking your dose and for at least one hour after taking it. Taking this medicine with food can cause your body to absorb too much of the drug, which may increase the risk of side effects.

The tablets should be swallowed whole with a glass of water. Do not crush, break, or chew the tablets. This medication is typically prescribed in combination with a steroid medication, such as prednisone or prednisolone, to help manage certain side effects.

Missed Dose

If you miss a dose of Zytiga, skip the missed dose and take your next dose at the regularly scheduled time the following day. Do not take two doses at once to make up for a missed one. If you miss more than one dose, contact your healthcare provider for instructions on how to proceed.

Question 8

Is Zytiga safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy and Fetal Risk

Zytiga is not indicated for use in women. Clinical data suggests that exposure to this medication during pregnancy can cause significant harm to a developing fetus or lead to birth defects. The medication can be absorbed through the skin; therefore, women who are pregnant or who may become pregnant are advised to avoid handling the tablets. If handling is required, the use of protective gloves is recommended.

Precautions for Men

Because Zytiga may be present in semen, men with female partners of reproductive potential typically use effective contraception during and after treatment. This often includes:

Using a condom along with another effective method of birth control during sexual activity.
Maintaining these contraceptive practices for 3 weeks following the final dose of the medication.

Breastfeeding

Zytiga is not for use in women, and there is no information available regarding its safety during breastfeeding. It is unknown if the drug passes into human breast milk or what effects it may have on a nursing infant.

Question 9

What forms and strengths does Zytiga come in?

Accepted Answer

Zytiga is available in the following oral forms:

Tablets
Film-coated tablets

This medication is administered by mouth. It must be taken on an empty stomach, as consuming food with the medication can significantly increase the amount of the drug absorbed by the body, potentially leading to increased side effects.

Question 10

What is the FDA approval status of Zytiga?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) first approved Zytiga (abiraterone acetate) in April 2011. Initially, it was approved for patients with metastatic castration-resistant prostate cancer who had already undergone chemotherapy. Its use was later expanded in 2012 to include patients who had not yet received chemotherapy, and in 2018 for those with metastatic high-risk castration-sensitive prostate cancer.

Approved Indications

Zytiga is approved for use in combination with prednisone for the treatment of:

Metastatic castration-resistant prostate cancer (mCRPC).
Metastatic high-risk castration-sensitive prostate cancer (mCSPC).

Safety and Monitoring

While Zytiga does not have a Boxed Warning or a Risk Evaluation and Mitigation Strategy (REMS) program, the FDA requires specific monitoring due to risks of hepatotoxicity (liver toxicity), hypertension, and hypokalemia. Patients must have their liver function and blood pressure monitored regularly while taking this medication.

Question 11

What should I know about Zytiga and cost?

Accepted Answer

Cost Factors

The price of Zytiga can vary based on several factors, including the patient's insurance plan, the pharmacy used, and the prescribed dosage. Because it is a specialty medication, out-of-pocket costs can be significant.

Generic Availability

A generic version of Zytiga, known as abiraterone acetate, is available. Generic medications contain the same active ingredients as brand-name drugs but are typically much less expensive. Many insurance plans may require the use of the generic version to manage treatment costs.

Insurance and Medicare Coverage

Most private insurance plans and Medicare Part D provide coverage for abiraterone. However, the drug is often placed on a higher cost-sharing tier, which may require patients to pay a percentage of the cost (coinsurance) rather than a fixed copay. It is advisable to check with the insurance provider for specific coverage details and any prior authorization requirements.

Financial Assistance Programs

Several options may help reduce the cost of Zytiga:

Manufacturer Support: The drug's manufacturer may offer copay cards or assistance programs for eligible patients with commercial insurance.
Patient Assistance Foundations: Independent non-profit organizations may provide financial aid to help cover the cost of cancer treatments for those who qualify.
Medicare Extra Help: Individuals with Medicare who have limited income and resources may qualify for assistance with their prescription drug costs.

Zytiga

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Zytiga

Hospitals.net Disclosure